Trial Profile
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Atuzaginstat (Primary)
- Indications Alzheimer's disease; Periodontal disorders
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms GAIN
- Sponsors Cortexyme
- 04 Aug 2022 Results assessing efficacy of atuzaginstat reducing cognitive decline in P. gingivalis infected subjects with mild-moderate alzheimers disease, presented at the Alzheimer's Association International Conference 2022.
- 21 Mar 2022 Results presented in the Cortexyme Media Release.
- 14 Mar 2022 According to a Cortexyme media release, data from this trial will be presented at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases. More data will become available throughout 2022 at additional conferences.